Clinical trial results:
A phase III, single group, open study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate vaccine in Taiwan when co-administered with GSK Biologicals' Infanrix hexa (DTPa-HBV-IPV/Hib) vaccine as a 3-dose primary immunization course at 1.5; 3 and 6 months of age and GSK Biologicals' Rotarix vaccine (HRV) as a 2-dose primary immunization course at 1.5 and 3 months of age.

Summary

EudraCT number	2015-001511-12
Trial protocol	Outside EU/EEA
Global end of trial date	06 June 2008

Results information

Result version number	v1
This version publication date	22 March 2016
First version publication date	29 July 2015

Trial information

Trial identification

Sponsor protocol code	109861

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00533507
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 October 2008
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	06 June 2008
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine in Taiwan, one month post dose 3, when co-administered with GSK Biologicals' Infanrix hexa and GSK Biologicals' Rotarix vaccines

Protection of trial subjects:

All subjects were supervised closely for at least 30 minutes following vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines. Subjects were followed-up from the time the subject consents to participate in the study until she/he is discharged.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 September 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Taiwan: 230
Worldwide total number of subjects	230
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	230
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Synflorix group

Arm description:

Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.

Arm type	Experimental
Investigational medicinal product name	Synflorix
Investigational medicinal product code	
Other name	10Pn-PD-DiT, Pneumococcal conjugate vaccine GSK1024850A
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

The vaccine was injected intramuscularly in the right thigh at 1.5, 3 and 6 months of age.

Investigational medicinal product name	Infanrix hexa
Investigational medicinal product code	
Other name	DTPa-HBV-IPV/Hib
Pharmaceutical forms	Powder and suspension for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

The vaccine was injected intramuscularly in the left thigh, at 1.5, 3 and 6 months of age.

Investigational medicinal product name	Rotarix
Investigational medicinal product code	
Other name	HRV vaccine
Pharmaceutical forms	Powder and solvent for oral suspension
Routes of administration	Oral use

Dosage and administration details:

The vaccine was administered orally at 1.5 and 3 months of age.

Number of subjects in period 1	Synflorix group
Started	230
Completed	229
Not completed	1
Consent withdrawn by subject	1

Baseline characteristics

Reporting groups	
Reporting group title	Synflorix group
Reporting group description:	
Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.	

Reporting group values	Synflorix group	Total	
Number of subjects	230	230	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: weeks			
arithmetic mean	6.4		
standard deviation	± 0.6	-	
Gender categorical			
Units: Subjects			
Female	115	115	
Male	115	115	

End points

End points reporting groups

Reporting group title	Synflorix group

Reporting group description:

Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.

Primary: Concentration of Anti-Protein D Antibodies

End point title	Concentration of Anti-Protein D Antibodies[1]

End point description:

Concentrations are given as geometric mean concentrations (GMC) and expressed in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).

End point type	Primary

End point timeframe:

One month after the third dose

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	219			
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Concentration of Anti-Protein D Antibodies	2277.6 (2048.7 to 2532.1)			

Statistical analyses

No statistical analyses for this end point

Primary: Concentration of Anti-Pneumococcal Antibodies

End point title	Concentration of Anti-Pneumococcal Antibodies[2]

End point description:

Concentrations are given as geometric mean titers (GMC) and expressed in microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

End point type	Primary

End point timeframe:

One month after the third dose

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was

performed.

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	219			
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-1	2.92 (2.65 to 3.22)			
Anti-4	3.79 (3.42 to 4.19)			
Anti-5	4.5 (4.11 to 4.93)			
Anti-6B	1.69 (1.47 to 1.94)			
Anti-7F	4.07 (3.72 to 4.46)			
Anti-9V	3.9 (3.51 to 4.32)			
Anti-14	5.69 (5.1 to 6.35)			
Anti-18C	7.28 (6.43 to 8.25)			
Anti-19F	8.04 (7.37 to 8.78)			
Anti-23F	2.81 (2.44 to 3.22)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Anti-Protein D Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-Protein D Antibody Concentrations Above the Cut-Off Value

End point description:

Anti-protein D antibody cut-off value assessed was greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).

End point type	Secondary

End point timeframe:

Before the first dose (pre) and one month after (post) the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	219			
Units: Subjects				
Pre (N=217)	38			
Post (N=219)	218			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value

End point description:

Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

End point type	Secondary

End point timeframe:

Before the first dose (pre) and one month after (post) the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	219			
Units: Subjects				
Anti-1 Pre (N=217)	111			
Anti-1 Post (N=219)	219			
Anti-4 Pre (N=217)	85			
Anti-4 Post (N=219)	219			
Anti-5 Pre (N=217)	149			
Anti-5 Post (N=219)	219			
Anti-6B Pre (N=217)	107			
Anti-6B Post (N=219)	215			
Anti-7F Pre (N=218)	138			
Anti-7F Post (N=219)	219			
Anti-9V Pre (N=218)	123			
Anti-9V Post (N=219)	219			
Anti-14 Pre (N=218)	203			
Anti-14 Post (N=219)	219			
Anti-18C Pre (N=219)	153			
Anti-18C Post (N=219)	219			
Anti-19F Pre (N=219)	172			
Anti-19F Post (N=219)	219			
Anti-23F Pre (N=219)	91			
Anti-23F Post (N=219)	216			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Cross-Reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Cross-Reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value

End point description:

Number of Subjects With Cross-Reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value

End point type	Secondary

End point timeframe:

One month after the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	219			
Units: Subjects				
Anti-6A (N=219)	210			
Anti-19A (N=218)	200			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-Off Value

End point title	Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-Off Value

End point description:

Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was greater than or equal to 1:8 titer.

End point type	Secondary

End point timeframe:

One month after the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	103			
Units: Subjects				
Opsono-1 (N=102)	98			
Opsono-4 (N=103)	103			
Opsono-5 (N=102)	101			
Opsono-6B (N=102)	89			
Opsono-7F (N=103)	103			
Opsono-9V (N=98)	98			
Opsono-14 (N=102)	101			
Opsono-18C (N=101)	99			
Opsono-19F (N=103)	101			
Opsono-23F (N=102)	98			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Opsonophagocytic Activity Against Cross-Reactive Pneumococcal Serotypes Above the Cut-Off Value

End point title	Number of Subjects With Opsonophagocytic Activity Against Cross-Reactive Pneumococcal Serotypes Above the Cut-Off Value

End point description:

Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was greater than or equal to 1:8 titer.

End point type	Secondary

End point timeframe:

One month after the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	97			
Units: Subjects				
Opsono-6A	87			
Opsono-19A	38			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Anti-Polyribosyl-Ribitol Phosphate Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-Polyribosyl-Ribitol Phosphate Antibody Concentrations Above the Cut-Off Value

End point description:

Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was greater than or equal to 0.15 microgram per milliliter (µg/mL).

End point type	Secondary

End point timeframe:

One month after the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	58			
Units: Subjects				
Anti-Polyribosyl-Ribitol Phosphate	58			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Anti-Diphteria and Anti-Tetanus Toxoids Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-Diphteria and Anti-Tetanus Toxoids Antibody Concentrations Above the Cut-Off Value

End point description:

Anti-diphteria and anti-tetanus toxoids antibody cut-off values assessed were greater than or equal to 0.10 International Units per milliliter (IU/mL).

End point type	Secondary

End point timeframe:

One month after the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	58			
Units: Subjects				
Anti-diphteria toxoid	58			
Anti-tetanus toxoid	58			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Anti-Pertussis (PT), Anti-Filamentous

Hemagglutinin (FHA) and Anti-Pertactin (PRN) Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-Pertussis (PT), Anti-Filamentous Hemagglutinin (FHA) and Anti-Pertactin (PRN) Antibody Concentrations Above the Cut-Off Value

End point description:

Anti-PT, anti-FHA and anti-PRN cut-off values assessed were greater than or equal to 5 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).

End point type	Secondary

End point timeframe:

One month after the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	58			
Units: Subjects				
Anti-PT (N=58)	58			
Anti-FHA (N=58)	58			
Anti-PRN (N=57)	57			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-Off Value

End point description:

Anti-HBs antibody cut-off value assessed was greater than or equal to 10 milli-International Units per milliliter (mIU/mL).

End point type	Secondary

End point timeframe:

One month after the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	32			
Units: Subjects				
Anti-Hepatitis B Surface Antigen (HBs)	32			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Anti-Poliovirus 1, 2 and 3 Antibody Titers Above the Cut-Off Value

End point title	Number of Subjects With Anti-Poliovirus 1, 2 and 3 Antibody Titers Above the Cut-Off Value

End point description:

Anti-poliovirus 1, 2 and 3 antibody cut-off value assessed was greater than or equal to 1:8 titer.

End point type	Secondary

End point timeframe:

One month after the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Subjects				
Anti-poliovirus 1	44			
Anti-poliovirus 2	44			
Anti-poliovirus 3	44			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Anti-rotavirus Immunoglobulin A antibody concentrations Above the Cut-Off Value

End point title	Number of Subjects With Anti-rotavirus Immunoglobulin A antibody concentrations Above the Cut-Off Value

End point description:

Anti-rotavirus IgA antibody cut-off value assessed was greater than or equal to 20 Units per milliliter (U/mL).

End point type	Secondary

End point timeframe:

Four months after the administration of the second dose of Rotarix™ vaccine

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: Subjects				
Anti-rotavirus Immunoglobulin A	44			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting solicited local symptoms

End point title	Number of subjects reporting solicited local symptoms

End point description:

Solicited local symptoms assessed include pain, redness and swelling.

End point type	Secondary

End point timeframe:

During the 4-day (Day 0-3) period after each dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	230			
Units: Subjects				
Pain Dose 1 (N=230)	99			
Redness Dose 1 (N=230)	99			
Swelling Dose 1 (N=230)	85			
Pain Dose 2 (N=229)	90			
Redness Dose 2 (N=229)	91			
Swelling Dose 2 (N=229)	83			
Pain Dose 3 (N=227)	83			
Redness Dose 3 (N=227)	107			
Swelling Dose 3 (N=227)	95			
Pain Across Doses (N=230)	146			
Redness Across Doses (N=230)	144			
Swelling Across Doses (N=230)	139			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting unsolicited adverse events (AE)

End point title	Number of subjects reporting unsolicited adverse events (AE)

End point description:

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product

End point type	Secondary

End point timeframe:

During the 31-day (Day 0-30) period after each dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	230			
Units: Subjects				
AEs	95			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting serious adverse events (SAE)

End point title	Number of subjects reporting serious adverse events (SAE)

End point description:

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

End point type	Secondary

End point timeframe:

Up to one month after the third dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	230			
Units: Subjects				
SAEs	15			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with solicited general symptoms

End point title	Number of subjects with solicited general symptoms

End point description:

Solicited general symptoms assessed include diarrhoea, drowsiness, fever, irritability, loss of appetite, and vomiting

End point type	Secondary

End point timeframe:
During the 4-day (Day 0-3) period after each dose

End point values	Synflorix group			
Subject group type	Reporting group			
Number of subjects analysed	230			
Units: Subjects				
Diarrhoea Dose 1 (N=230)	6			
Drowsiness Dose 1 (N=230)	153			
Fever Dose 1 (N=230)	115			
Irritability Dose 1 (N=230)	154			
Loss of Appetite Dose 1 (N=230)	95			
Vomiting Dose 1 (N=230)	30			
Diarrhoea Dose 2 (N=229)	1			
Drowsiness Dose 2 (N=229)	126			
Fever Dose 2 (N=229)	81			
Irritability Dose 2 (N=229)	138			
Loss of Appetite Dose 2 (N=229)	99			
Vomiting Dose 2 (N=229)	22			
Diarrhoea Dose 3 (N=227)	0			
Drowsiness Dose 3 (N=227)	105			
Fever Dose 3 (N=227)	60			
Irritability Dose 3 (N=227)	131			
Loss of Appetite Dose 3 (N=227)	87			
Vomiting Dose 3 (N=227)	21			
Diarrhoea Across Doses (N=230)	7			
Drowsiness Across Doses (N=230)	190			
Fever Across Doses (N=230)	153			
Irritability Across Doses (N=230)	203			
Loss of Appetite Across Doses (N=230)	159			
Vomiting Across Doses (N=230)	55			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited symptoms: during the 4 days (Day 0-Day 3) following vaccination.
Unsolicited AEs: during the 31 days (Day 0-Day 30) following vaccination.
SAEs: during the entire study.

Adverse event reporting additional description:

The occurrence of reported AEs (all/related) was not available and is encoded as equal to the number of subjects affected.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	11.0

Reporting groups

Reporting group title	Synflorix Group

Reporting group description:

Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.

Serious adverse events	Synflorix Group		
Total subjects affected by serious adverse events			
subjects affected / exposed	15 / 230 (6.52%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	2 / 230 (0.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Enterocolitis			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Bronchial hyperreactivity			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dermatitis diaper			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Vesicoureteric reflux			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	6 / 230 (2.61%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Bronchiolitis			
subjects affected / exposed	4 / 230 (1.74%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	2 / 230 (0.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bronchopneumonia			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis bacterial			

subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Kawasaki's disease			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Meningitis aseptic			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 230 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Synflorix Group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	203 / 230 (88.26%)		
General disorders and administration site conditions			
Pain			
alternative assessment type: Systematic			
subjects affected / exposed	146 / 230 (63.48%)		
occurrences (all)	146		
Redness			
alternative assessment type: Systematic			

subjects affected / exposed	144 / 230 (62.61%)		
occurrences (all)	144		
Swelling			
alternative assessment type: Systematic			
subjects affected / exposed	139 / 230 (60.43%)		
occurrences (all)	139		
Drowsiness			
alternative assessment type: Systematic			
subjects affected / exposed	190 / 230 (82.61%)		
occurrences (all)	190		
Fever			
alternative assessment type: Systematic			
subjects affected / exposed	153 / 230 (66.52%)		
occurrences (all)	153		
Irritability			
alternative assessment type: Systematic			
subjects affected / exposed	203 / 230 (88.26%)		
occurrences (all)	203		
Loss of appetite			
alternative assessment type: Systematic			
subjects affected / exposed	159 / 230 (69.13%)		
occurrences (all)	159		
Vomiting			
alternative assessment type: Systematic			
subjects affected / exposed	55 / 230 (23.91%)		
occurrences (all)	55		
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	54 / 230 (23.48%)		
occurrences (all)	54		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 November 2007	This amendment is made following the request from the country to perform immunogenicity analyses of the co-administered vaccines in a subset of subjects.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported